Zhao Ming, Wang Ke-Jing, Tan Zhuo, Zheng Chuan-Ming, Liang Zhong, Zhao Jian-Qiang
Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Oncol Lett. 2016 Jan;11(1):51-58. doi: 10.3892/ol.2015.3829. Epub 2015 Oct 26.
The aim of the present study was to identify potential therapeutic targets for papillary thyroid carcinoma (PTC) and to investigate the possible mechanism underlying this disease. The gene expression profile, GSE53157, was downloaded from the Gene Expression Omnibus database. Only 10 chips, including 3 specimens of normal thyroid tissues and 7 specimens of well-differentiated thyroid carcinomas, were analyzed in the present study. Differentially-expressed genes (DEGs) between PTC patients and normal individuals were identified. Next, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses of DEGs were performed. Modules in the protein-protein interaction (PPI) network were identified. Significant target genes were selected from the microRNA (miRNA) regulatory network. Furthermore, the integrated network was constructed with the miRNA regulatory and PPI network modules, and key target genes were screened. A total of 668 DEGs were identified. Modules M1, M2 and M3 were identified from the PPI network. From the modules, DEGs of cyclin-dependent kinase inhibitor 1A, S100 calcium binding protein A6 (S100A6), dual specificity phosphatase 5, keratin 19, met proto-oncogene (MET) and lectin galactoside-binding soluble 3 were included in the Malacards database. In the miRNA regulatory and integrated networks, genes of cyclin-dependent kinase inhibitor 1C (CDKN1C), peroxisome proliferator-activated receptor γ, aryl hydrocarbon receptor, basic helix-loop-helix family, member e40 and reticulon 1 were the key target genes. S100A6, MET and CDKN1C may exhibit key roles in the progression and development of PTC, and may be used as specific therapeutic targets in the treatment of PTC. However, further experiments are required to confirm these results.
本研究的目的是确定甲状腺乳头状癌(PTC)的潜在治疗靶点,并探究该疾病的潜在机制。基因表达谱GSE53157从基因表达综合数据库下载。本研究仅分析了10个芯片,包括3个正常甲状腺组织样本和7个高分化甲状腺癌样本。确定了PTC患者与正常个体之间的差异表达基因(DEGs)。接下来,对DEGs进行了基因本体论和京都基因与基因组百科全书通路分析。确定了蛋白质-蛋白质相互作用(PPI)网络中的模块。从微小RNA(miRNA)调控网络中选择了重要的靶基因。此外,用miRNA调控和PPI网络模块构建了整合网络,并筛选了关键靶基因。共鉴定出668个DEGs。从PPI网络中确定了模块M1、M2和M3。在这些模块中,细胞周期蛋白依赖性激酶抑制剂1A、S100钙结合蛋白A6(S100A6)、双特异性磷酸酶5、角蛋白19、原癌基因(MET)和半乳糖凝集素可溶性3的DEGs被纳入Malacards数据库。在miRNA调控和整合网络中,细胞周期蛋白依赖性激酶抑制剂1C(CDKN1C)、过氧化物酶体增殖物激活受体γ、芳烃受体、碱性螺旋-环-螺旋家族成员e40和网织蛋白1的基因是关键靶基因。S100A6、MET和CDKN1C可能在PTC的进展和发展中发挥关键作用,并可能作为PTC治疗的特异性治疗靶点。然而,需要进一步的实验来证实这些结果。